Revolution Medicines, Inc.(RVMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

RVMD Revolution Medicines, Inc.

Post-Mkt 10-08 16:45:43 EDT

188.12

-12.75

-6.35%

盘后189.86

+1.74+0.93%

16:44 EDT

High199.64	Low180.49	Vol4.86M
Open198.51	D1 Closing200.87	Amplitude9.53%
Mkt Cap40.32B	Tradable Cap34.80B	Total Shares214.34M
T/O902.98M	T/O Rate2.62%	Tradable Shares185.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"RVMD","market":"US","secType":"STK","nameCN":"Revolution Medicines, Inc.","latestPrice":188.12,"timestamp":1791489600000,"preClose":200.87,"halted":0,"volume":4855567,"hourTrading":{"tag":"盘后","latestPrice":189.8614,"preClose":188.12,"latestTime":"16:44 EDT","volume":4960,"amount":933073.2655999999,"timestamp":1791492241089,"change":1.7414,"changeRate":0.009257,"amplitude":0.014848},"delay":0,"changeRate":-0.06347388858465675,"floatShares":185000000,"shares":214336418,"eps":-8.921187,"marketStatus":"Post-Mkt","change":-12.75,"latestTime":"10-08 16:45:43 EDT","open":198.51,"high":199.64,"low":180.49,"amount":902977704.62817,"amplitude":0.095335,"askPrice":192,"askSize":22,"bidPrice":183.11,"bidSize":2,"shortable":0,"etf":0,"ttmEps":-8.921187,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1791504000000},"marketStatusCode":4,"adr":0,"listingDate":1581570000000,"exchange":"NASDAQ","adjPreClose":200.87,"preHourTrading":{"tag":"盘前","latestPrice":198.52,"preClose":200.87,"latestTime":"09:29 EDT","volume":691,"amount":137685.77853,"timestamp":1791466199999,"change":-2.35,"changeRate":-0.011699,"amplitude":0.034799},"postHourTrading":{"tag":"盘后","latestPrice":189.8614,"preClose":188.12,"latestTime":"16:44 EDT","volume":4960,"amount":933073.2655999999,"timestamp":1791492241089,"change":1.7414,"changeRate":0.009257,"amplitude":0.014848},"volumeRatio":3.066679,"impliedVol":0.5473,"impliedVolPercentile":0.4263},"requestUrl":"/m/hq/s/RVMD/tweets","defaultTab":"tweets","newsList":[{"id":"2674074190","title":"RBC would be buyers of Revolution Medicines after FDA docs ‘overreaction’","url":"https://stock-news.laohu8.com/highlight/detail?id=2674074190","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674074190?lang=en_us&edition=fundamental","pubTime":"2026-10-09 03:45","pubTimestamp":1791488724,"startTime":"0","endTime":"0","summary":"RBC Capital notes Revolution Medicines (RVMD) looks to be down in response to yesterday’s disclosure of FDA’s Rasonque review documents, particular...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/rbc-would-be-buyers-of-revolution-medicines-after-fda-docs-overreaction-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/rbc-would-be-buyers-of-revolution-medicines-after-fda-docs-overreaction-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBH","IE0009355771.USD","IE00B4R5TH58.HKD","GSIB","LABU","LU0889565916.HKD","IE00BJJMRZ35.SGD","IE0002141913.USD","LU0310800379.SGD","LU0708994859.HKD","BK4139","LU0109394709.USD","LU0029864427.USD","PTH","IE00BJT1NW94.SGD","RVMD","IE0009354923.USD","LU0320765992.SGD","BK4588","IDNA","IE00B2B36J28.USD","LU0128525929.USD","BK4207","BK4585","LU1267930573.SGD","CANC","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674077820","title":"Revolution Medicines selloff ‘overdone and misguided,’ says TD Cowen","url":"https://stock-news.laohu8.com/highlight/detail?id=2674077820","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674077820?lang=en_us&edition=fundamental","pubTime":"2026-10-09 03:40","pubTimestamp":1791488425,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Tyler Van Buren reiterated a Buy rating on Revolution Medicines (RVMD), saying Thursday’s selloff on Rasonque’s reported efficacy ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/revolution-medicines-selloff-overdone-and-misguided-says-td-cowen-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/revolution-medicines-selloff-overdone-and-misguided-says-td-cowen-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0002141913.USD","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","COWN","BBH","LU0109394709.USD","IE0009354923.USD","BK4127","IE00B2B36J28.USD","IDNA","IE00BFTCPJ56.SGD","CANC","LU0320765992.SGD","LU0889565916.HKD","PTH","IE0009355771.USD","BK4139","RVMD","IE00BJJMRZ35.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674004785","title":"Revolution Medicines Falls on Pancreatic Cancer Drug Data Concerns","url":"https://stock-news.laohu8.com/highlight/detail?id=2674004785","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674004785?lang=en_us&edition=fundamental","pubTime":"2026-10-09 02:17","pubTimestamp":1791483427,"startTime":"0","endTime":"0","summary":"BUZZ-Revolution Medicines falls on pancreatic cancer drug data concerns** Shares of Revolution MedicinesRVMD.Odown 8.1% at $185.91 in afternoon trading** RBC Capital Markets says stock looks to be dow","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261008:nL4N45U1II:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBH","RVMD","CANC","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","BK4139","IE0002141913.USD","LU0889565916.HKD","LU0109394709.USD","IE00BJJMRZ35.SGD","LU0320765992.SGD","IE0009355771.USD","PTH","IDNA","IE00B2B36J28.USD","IE0009354923.USD","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674091230","title":"Revolution trading down after daraxonrasib review docs, says Stifel","url":"https://stock-news.laohu8.com/highlight/detail?id=2674091230","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674091230?lang=en_us&edition=fundamental","pubTime":"2026-10-09 00:05","pubTimestamp":1791475557,"startTime":"0","endTime":"0","summary":"Stifel says shares of Revolution Medicines (RVMD) are lower after the FDA posted multidisciplinary review documents for daraxonrasib with additiona...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/revolution-trading-down-after-daraxonrasib-review-docs-says-stifel-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/revolution-trading-down-after-daraxonrasib-review-docs-says-stifel-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0009355771.USD","IE00BJT1NW94.SGD","BK4588","RVMD","BK4585","CANC","IE0009354923.USD","IE00B2B36J28.USD","IE0002141913.USD","BBH","LU0109394709.USD","LU0889565916.HKD","IE00BJJMRZ35.SGD","IDNA","IE00B4R5TH58.HKD","LU0320765992.SGD","LABU","PTH","BK4139","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152254217","title":"Movement Alert｜Revolution Medicines, Inc. Falls 5.28% in Regular Trading, Biotech Sector Weakness Pressures Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1152254217","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152254217?lang=en_us&edition=fundamental","pubTime":"2026-10-08 21:58","pubTimestamp":1791467901,"startTime":"0","endTime":"0","summary":"On October 8, Revolution Medicines, Inc. fell 5.28% in regular trading, trading at $190.24/share, with Turnover of $65.13 million.The decline comes amid broad weakness across the biotechnology...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Revolution Medicines Falls as Biotech Sector Weakness Deepens","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673074882","title":"RBC Raises Price Target on Revolution Medicines to $259 From $251, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2673074882","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673074882?lang=en_us&edition=fundamental","pubTime":"2026-10-08 19:44","pubTimestamp":1791459843,"startTime":"0","endTime":"0","summary":"Revolution Medicines (RVMD) has an average rating of buy and mean price target of $259.19, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from maj","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673017021","title":"Will Phase 3 Trial Start Change Revolution Medicines (RVMD) Narrative","url":"https://stock-news.laohu8.com/highlight/detail?id=2673017021","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673017021?lang=en_us&edition=fundamental","pubTime":"2026-10-08 15:26","pubTimestamp":1791444398,"startTime":"0","endTime":"0","summary":"Revolution Medicines has already started treating patients in RASolute 309, a global Phase 3 trial testing RASONQUE plus zoldonrasib as first line therapy against standard gemcitabine and nab paclitaxel in metastatic RAS G12D pancreatic cancer, with progression free and overall survival as dual primary endpoints.\nThe study targets RAS G12D, the most prevalent RAS mutation across cancers, where roughly 61,000 new U.S. patients each year currently have no approved targeted therapy. This puts...","market":"nz","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rvmd/revolution-medicines/news/will-phase-3-trial-start-change-revolution-medicines-rvmd-na","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rvmd/revolution-medicines/news/will-phase-3-trial-start-change-revolution-medicines-rvmd-na","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IE00BJT1NW94.SGD","BK4139","LU0109394709.USD","IE00B2B36J28.USD","BK4141","IE00B4R5TH58.HKD","ON","LU0348723411.USD","LU2357305700.SGD","LU0724618433.USD","LU1861214812.USD","BK4605","LU1854103824.USD","IE00BFTCPJ56.SGD","LU2360107325.USD","ONX","BK4512","LU1978683503.SGD","IDNA","LU0889565916.HKD","CANC","ONG","LU1983260115.SGD","IE00BFMHRM44.USD","BK4588","IE00BD6J9T35.USD","LU1854104046.USD","LU1861215975.USD","LU0320765992.SGD","LU2298322129.HKD","IE0009354923.USD","IE0009355771.USD","IE0002141913.USD","PTH","LU1548497426.USD","LU1861219969.SGD","IE00BJJMRZ35.SGD","IE00BZ199S13.USD","LU0124384867.USD","BK4585","LU1720051108.HKD","RVMD","LU1861220033.SGD","BBH","LU1720051017.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673182850","title":"Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution Medicines’ Daraxonrasib","url":"https://stock-news.laohu8.com/highlight/detail?id=2673182850","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673182850?lang=en_us&edition=fundamental","pubTime":"2026-10-07 20:30","pubTimestamp":1791376200,"startTime":"0","endTime":"0","summary":"Preclinical package also shows more than 2.5-fold survival extension in advanced PDAC models; Company contrasts a non-RAS, differentiation-based mechanism with the clinical benchmark set by RASONQUE (","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/07/3376463/0/en/propanc-biopharma-reports-data-showing-90-tumor-growth-inhibition-with-prp-in-pancreatic-cancer-models-contrasting-profile-with-revolution-medicines-daraxonrasib.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B2B36J28.USD","IE00B4R5TH58.HKD","LU0889565916.HKD","LU2298322129.HKD","BBH","BK4605","LU0320765992.SGD","IE00BFTCPJ56.SGD","LU2357305700.SGD","ON","LU1978683503.SGD","BK4141","LU1983260115.SGD","LU1548497426.USD","BK4585","LU1854103824.USD","IE00BFMHRM44.USD","IE00BD6J9T35.USD","ONG","IE00BJJMRZ35.SGD","IE0002141913.USD","LU0724618433.USD","LU1861219969.SGD","LU1861220033.SGD","LU1720051108.HKD","LU2360107325.USD","BK4512","LU0109394709.USD","LU1861215975.USD","LU1720051017.SGD","IE00BJT1NW94.SGD","LU0348723411.USD","RVMD","IDNA","LU0124384867.USD","IE0009354923.USD","IE00BZ199S13.USD","BK4588","PTH","LU1854104046.USD","BK4139","ONX","LU1861214812.USD","IE0009355771.USD","CANC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150694158","title":"Movement Alert｜Revolution Medicines, Inc. Falls 5.23% in Regular Trading, Biotechnology Sector Weakness Drags Down Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1150694158","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150694158?lang=en_us&edition=fundamental","pubTime":"2026-10-06 22:14","pubTimestamp":1791296047,"startTime":"0","endTime":"0","summary":"On October 6, Revolution Medicines, Inc. fell 5.23% in regular trading, trading at $196.54/share, with Turnover of $44.4953 million.The decline comes as the broader biotechnology sector experienced...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673177083","title":"Maintained Buy on Revolution Medicines: Strong RAS Franchise Momentum and ESMO GI 2026 Data Support Unchanged $315 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2673177083","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673177083?lang=en_us&edition=fundamental","pubTime":"2026-10-05 22:55","pubTimestamp":1791212119,"startTime":"0","endTime":"0","summary":"Analyst Charles Zhu from LifeSci Capital maintained a Buy rating on Revolution Medicines and keeping the price target at $315.00. Charles Zhu has g...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/maintained-buy-on-revolution-medicines-strong-ras-franchise-momentum-and-esmo-gi-2026-data-support-unchanged-315-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/maintained-buy-on-revolution-medicines-strong-ras-franchise-momentum-and-esmo-gi-2026-data-support-unchanged-315-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673702723","title":"Revolution Medicines Starts Phase 3 Trial of Rasonque-Zoldonrasib Combo in First-Line Metastatic RAS G12D Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2673702723","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673702723?lang=en_us&edition=fundamental","pubTime":"2026-10-05 20:14","pubTimestamp":1791202453,"startTime":"0","endTime":"0","summary":"Revolution Medicines starts Phase 3 trial of RASONQUE-zoldonrasib combo in first-line metastatic RAS G12D pancreatic cancerRevolution Medicines began dosing patients in a global Phase 3 trial testing ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nNDL1LgfsV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","IE00B4R5TH58.HKD","IE00BQXX3D17.EUR","BK4139","LU2210149790.SGD","LU0109394709.USD","IE00BQXX3C00.GBP","BBH","CANC","IE00BQXX3F31.USD","IE00BN0W2V16.EUR","BCDF","IE00BGHQF748.EUR","SG9999014021.USD","IDNA","IE00BN0W2T93.GBP","LU0889565916.HKD","RVMD","NDAQ","IE0009354923.USD","SG9999014039.USD","IE00BJT1NW94.SGD","IE00BN0W2W23.USD","LU2210150020.SGD","BK4588","BK4112","IE0002141913.USD","IE00B2B36J28.USD","LU2095319765.USD","IE00BFTCPJ56.SGD","IE00BKPKM429.USD","LU0320765992.SGD","PTH","LU0314104364.USD","IE0009355771.USD","IE00B64PRP62.GBP","SG9999014013.SGD","BK4585","SG9999014005.SGD","IE00BJJMRZ35.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673702923","title":"Revolution Medicines Begins Treating Patients in Phase 3 Rasolute 309 Trial Evaluating Rasonque™ (Daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic Ras G12d Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2673702923","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673702923?lang=en_us&edition=fundamental","pubTime":"2026-10-05 20:00","pubTimestamp":1791201603,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nTUA7YHCFD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BBH","IE0002141913.USD","LU0889565916.HKD","LU0320765992.SGD","IE0009354923.USD","IDNA","PTH","BK4139","IE00B2B36J28.USD","CANC","IE00BFTCPJ56.SGD","RVMD","IE00BJT1NW94.SGD","LU0109394709.USD","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673709483","title":"Revolution Medicines, Inc. : Leerink Partners Resumes Coverage with Outperform Rating; Price Target $288","url":"https://stock-news.laohu8.com/highlight/detail?id=2673709483","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673709483?lang=en_us&edition=fundamental","pubTime":"2026-10-05 18:11","pubTimestamp":1791195096,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nFWN45R0PU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IDNA","LU0889565916.HKD","LU0109394709.USD","IE00BJJMRZ35.SGD","BBH","BK4139","IE0009355771.USD","RVMD","IE00B4R5TH58.HKD","IE00B2B36J28.USD","PTH","IE0009354923.USD","LU0320765992.SGD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","CANC","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672476771","title":"Revolution Medicines Chief Development Officer Alan B. Sandler Disposes of USD 1,264,082 in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2672476771","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672476771?lang=en_us&edition=fundamental","pubTime":"2026-10-02 06:00","pubTimestamp":1790892038,"startTime":"0","endTime":"0","summary":"Revolution Medicines Chief Development Officer Alan B. Sandler disposes of USD 1,264,082 in common sharesRevolution Medicines Chief Development Officer Alan B. Sandler exercised stock options for 6,00","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nNDL9BczFC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Revolution Medicines Chief Development Officer Alan B. Sandler Disposes of USD 1,264,082 in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","IDNA","LU0889565916.HKD","IE0009355771.USD","PTH","IE0002141913.USD","BBH","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","CANC","LU0320765992.SGD","RVMD","IE00B2B36J28.USD","LU0109394709.USD","IE0009354923.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671013268","title":"Revolution Medicines Chief Global Commercialization Officer Anthony Mancini Sells USD 743,436 in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2671013268","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671013268?lang=en_us&edition=fundamental","pubTime":"2026-09-29 06:00","pubTimestamp":1790632843,"startTime":"0","endTime":"0","summary":"Revolution Medicines Chief Global Commercialization Officer Anthony Mancini sells USD 743,436 in common sharesRevolution Medicines Chief Global Commercialization Officer Anthony Mancini reported sales","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260928:nNDLcdFr5m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Revolution Medicines Chief Global Commercialization Officer Anthony Mancini Sells USD 743,436 in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","IE0002141913.USD","IE00B2B36J28.USD","IE0009354923.USD","LU0320765992.SGD","IE00BJT1NW94.SGD","IDNA","CANC","LU0109394709.USD","IE00B4R5TH58.HKD","BK4139","PTH","IE0009355771.USD","RVMD","IE00BJJMRZ35.SGD","BBH","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671251475","title":"Revolution Medicines Price Target Announced at $318.00/Share by Brookline Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2671251475","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671251475?lang=en_us&edition=fundamental","pubTime":"2026-09-29 01:05","pubTimestamp":1790615100,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RVMD/analyst-ratings","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671597742","title":"Buy Rating Reiterated on Revolution Medicines as KRAS G12D Lead Strengthens; $315 Price Target Maintained","url":"https://stock-news.laohu8.com/highlight/detail?id=2671597742","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671597742?lang=en_us&edition=fundamental","pubTime":"2026-09-29 00:05","pubTimestamp":1790611524,"startTime":"0","endTime":"0","summary":"Revolution Medicines, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Charles Zhu from LifeSci Capital maintai...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-reiterated-on-revolution-medicines-as-kras-g12d-lead-strengthens-315-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-reiterated-on-revolution-medicines-as-kras-g12d-lead-strengthens-315-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RVMD","DBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670259517","title":"Revolution Medicines Seen Having 'Strong' Rasonque Launch in Pancreatic Cancer, UBS Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2670259517","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670259517?lang=en_us&edition=fundamental","pubTime":"2026-09-28 23:58","pubTimestamp":1790611096,"startTime":"0","endTime":"0","summary":"Revolution Medicines (RVMD) is expected to have a \"strong\" launch for its Rasonque drug in second-line pancreatic ductal adenocarcinoma patients, and in some first-line patients as well, UBS Securitie","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE0009355771.USD","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","LU0320765992.SGD","PTH","IE0009354923.USD","IE00B4R5TH58.HKD","IDNA","IE00BJT1NW94.SGD","BK4139","LU0889565916.HKD","IE00B2B36J28.USD","RVMD","CANC","BBH","LU0109394709.USD","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670147451","title":"Bernstein Sticks to Their Hold Rating for Revolution Medicines (RVMD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2670147451","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670147451?lang=en_us&edition=fundamental","pubTime":"2026-09-26 22:25","pubTimestamp":1790432716,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Jeffrey Walch from Bernstein maintained a Hold rating on Revolution Medicines, with a price target of $179.00. The ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bernstein-sticks-to-their-hold-rating-for-revolution-medicines-rvmd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bernstein-sticks-to-their-hold-rating-for-revolution-medicines-rvmd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149833622","title":"Movement Alert｜Revolution Medicines, Inc. Rises 5.06% in Regular Trading, Multiple Banks Raise Price Targets Amid FDA Breakthrough Therapy Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=1149833622","media":"Market Focus","labels":["corporation","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149833622?lang=en_us&edition=fundamental","pubTime":"2026-09-25 23:47","pubTimestamp":1790351250,"startTime":"0","endTime":"0","summary":"On September 25, Revolution Medicines, Inc. rose 5.06% in regular trading, trading at $210.095 per share, with turnover of $192 million. The rally was fueled by a confluence of positive catalysts,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Revolution Medicines Soars as BofA Lifts Target to $265","news_tag":"corporation,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.revmed.com;ir.revmed.com","stockEarnings":[{"period":"1week","weight":-0.0214},{"period":"1month","weight":-0.0436},{"period":"3month","weight":0.051},{"period":"6month","weight":1.0831},{"period":"1year","weight":3.3133},{"period":"ytd","weight":1.5219}],"compareEarnings":[{"period":"1week","weight":0.0191},{"period":"1month","weight":0.0091},{"period":"3month","weight":0.0339},{"period":"6month","weight":0.1439},{"period":"1year","weight":0.1616},{"period":"ytd","weight":0.1398}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Revolution Medicines, Inc., a clinical-stage oncology company, developing novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) Inhibitors designed to suppress oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. The company's RAS(ON) Inhibitors RMC-6236 (RASMULTI), RMC-6291 (RASG12C), and RMC-9805 (RASG12D) are in clinical development. Its additional RAS(ON) Inhibitors in its pipeline include RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), which are in IND-enabling development, and additional compounds targeting other RAS variants. The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.034782},{"month":2,"riseRate":0.666667,"avgChangeRate":0.00452},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.031822},{"month":4,"riseRate":0.714286,"avgChangeRate":0.114077},{"month":5,"riseRate":0.428571,"avgChangeRate":-0.015463},{"month":6,"riseRate":0.857143,"avgChangeRate":0.063598},{"month":7,"riseRate":0.571429,"avgChangeRate":-0.000417},{"month":8,"riseRate":0.714286,"avgChangeRate":0.065126},{"month":9,"riseRate":0.428571,"avgChangeRate":0.032485},{"month":10,"riseRate":0.571429,"avgChangeRate":0.014044},{"month":11,"riseRate":0.833333,"avgChangeRate":0.188424},{"month":12,"riseRate":0.5,"avgChangeRate":-0.027192}],"exchange":"NASDAQ","name":"Revolution Medicines, Inc.","nameEN":"Revolution Medicines, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Revolution Medicines, Inc.(RVMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Revolution Medicines, Inc.(RVMD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Revolution Medicines, Inc.,RVMD,Revolution Medicines, Inc.股票,Revolution Medicines, Inc.股票老虎,Revolution Medicines, Inc.股票老虎国际,Revolution Medicines, Inc.行情,Revolution Medicines, Inc.股票行情,Revolution Medicines, Inc.股价,Revolution Medicines, Inc.股市,Revolution Medicines, Inc.股票价格,Revolution Medicines, Inc.股票交易,Revolution Medicines, Inc.股票购买,Revolution Medicines, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Revolution Medicines, Inc.(RVMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Revolution Medicines, Inc.(RVMD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}